Fennec Pharmaceuticals (FRX) Set to Announce Earnings on Thursday

Fennec Pharmaceuticals (TSE:FRX) is scheduled to release its earnings data before the market opens on Thursday, November 7th. Analysts expect Fennec Pharmaceuticals to post earnings of C($0.19) per share for the quarter.

Fennec Pharmaceuticals (TSE:FRX) last issued its earnings results on Tuesday, August 13th. The biopharmaceutical company reported C($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of C$0.08 by C($0.35). Fennec Pharmaceuticals had a negative return on equity of 1,005.59% and a net margin of 5.59%. The company had revenue of C$9.94 million during the quarter, compared to analyst estimates of C$18.67 million.

Fennec Pharmaceuticals Trading Up 11.5 %

Shares of TSE:FRX traded up C$0.70 during midday trading on Tuesday, reaching C$6.78. The company had a trading volume of 1,060 shares, compared to its average volume of 1,814. The company has a fifty day simple moving average of C$6.72 and a two-hundred day simple moving average of C$8.56. The company has a debt-to-equity ratio of 1,040.68, a quick ratio of 10.17 and a current ratio of 8.02. The firm has a market cap of C$185.50 million, a price-to-earnings ratio of 60.80 and a beta of 0.25. Fennec Pharmaceuticals has a 1-year low of C$5.76 and a 1-year high of C$15.43.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.